Erasca, Inc.
ERAS
Rangering i aksjer
#3403
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Aksjekurs
$14.62
Sist synkronisert: 2026-10-20
Markedsverdi
$5.11B
Endring (1 dag)
7.34%
Endring (1 år)
514.29%
Land
US
Handel Erasca, Inc. (ERAS)
Kategori
Healthcare
Historikk for aksjesplitt for Erasca, Inc. (ERAS)
Aksjen Erasca, Inc. (symbol: ERAS) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én ERAS-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 ERAS-aksjer.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én ERAS-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 ERAS-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
